Blog

Nov 04, 2024

Is a Globus Medical, Inc. (GMED) Promising Medical Stock with Growth Potential?

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds . In this article, we are going to take a look at where Globus Medical, Inc. (NYSE:GMED) stands against other

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to take a look at where Globus Medical, Inc. (NYSE:GMED) stands against other most promising medical stocks.

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, and treatment. Unlike pharmaceuticals, medical devices work through physical or mechanical means rather than chemical processes. Key products include pacemakers, imaging equipment, dialysis machines, and implants.

Like many other industries, the medical device industry was greatly affected by the start of the COVID-19 pandemic. Interestingly, the In Vitro Diagnostics (IVD) segment saw significant revenue growth in 2020 and 2021, mostly due to the increased demand for PCR and fast testing. Overall, even while funding for digital health had been rising gradually in the years preceding the pandemic, it saw a notable uptick in 2021, hitting around $45 billion, more than all of the funds amassed between 2010 and 2017.

The global market for medical devices, estimated to be worth $570 billion in 2022, is expected to increase at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2032, reaching over $996.93 billion. By 2032, the U.S. market is expected to have grown to a value of around $246.51 billion, with a compound annual growth rate (CAGR) of 5.6%. Key drivers propelling the medical devices market’s expansion in the upcoming years are the rise in demand for cutting-edge treatments and continuous technical developments in medical devices to meet unmet demands in the healthcare industry.

The importance of the medical devices sector, which employed over 329,000 people and generated $25.8 billion in payroll in 2020, is highlighted by the U.S. Cluster Mapping Tool. The 2023 EY Medical Technology study highlights supply chain management and financing as two important topics for Medtech leaders worldwide. In 2022, R&D expenditure returned to historical norms, despite reaching a record $24.7 billion. A significant drop in mergers and acquisitions is also noted in the report which indicates a diminished emphasis on inorganic growth tactics.

Artificial intelligence (AI) and other technologies have revolutionized patient monitoring, diagnosis, and treatment in the healthcare industry. Applications of AI include predicting results using electronic health information and evaluating radiological images for early detection. One noteworthy instance was when NVIDIA Corporation and Medtronic announced in March 2023 that they would be integrating NVIDIA’s AI technology into Medtronic’s FDA-approved GI Genius, an intelligent endoscopic module that helps detect precancerous growths.

Also Read 10 Best Healthcare Stocks to Buy According to Hedge Funds and 10 Best Mid-Cap Healthcare Stocks to Buy Now.

For our methodology, we began by filtering medical stocks from healthcare equipment ETFs. Next, we identified those with the highest number of hedge fund holders as of Q2 2024, using data from the Insider Monkey database. The final selection was ranked based on the number of hedge fund holders to prioritize stocks with greater institutional interest.

“Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).”

A medical professional conducting a minimally invasive procedure using a cutting-edge medical device.

Number of Hedge Fund Holders: 38

Globus Medical, Inc. (NYSE:GMED) is a leading medical device company that specializes in musculoskeletal solutions. It develops, manufactures, and distributes innovative implants and instruments for spinal, orthopedic, and neurosurgical procedures. Its product portfolio includes spinal implants, biologics, and enabling technologies such as robotic navigation systems.

In Q2 2024, Globus Medical reported revenue of $629.7 million, a remarkable 115.93% increase from $291.6 million in Q2 2023, largely driven by the acquisition of NuVasive. U.S. sales rose by 103.5%, while international sales surged by 182.3% (191.3% on a constant currency basis).

Despite strong revenue growth, Globus Medical, Inc. (NYSE:GMED)’s profitability metrics were mixed. GAAP net income decreased by 45% to $31.8 million, and GAAP diluted EPS fell to $0.23 from $0.57 in the previous year. However, non-GAAP diluted EPS improved to $0.75 from $0.63, and adjusted EBITDA increased by 98% to $190.4 million. The decline in GAAP metrics is attributed to high merger-related costs and amortization expenses, but the improvement in non-GAAP figures indicates underlying operational efficiency.

Here is what Daniel Scavilla, the company’s president and CEO said about the company’s performance in its Q2 call earning transcript:

“From pioneering the XLIF procedure that is now the gold standard of lateral surgery, leading the market in expandable spacer technology, and developing the best spinal robot with the most advanced interoperative CT imaging, we are working to create surgical proceduralization of all key spine surgeries to create the standard of care across the spine industry. Our intellectual property portfolio has been number one in the spinal industry for the last decade, and Globus is committed to further expanding this lead, especially in the enabling tech arenas, as we continue to be at the forefront of imaging, navigation, and robotics. To accomplish this, we remain committed to continuing existing projects, and we’ll have an ongoing PD presence on the West Coast focused on spine and neuromonitoring solutions.”

Overall, GMED ranks 5th on our list of most promising medical stocks according to hedge funds. While we acknowledge the potential of GMED as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than GMED but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.